These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 387341)

  • 21. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation.
    Taylor DO; Kfoury AG; Pisani B; Hammond EH; Renlund DG
    Transplant Proc; 1997 Dec; 29(8A):13S-15S. PubMed ID: 9414668
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
    Langrehr JM; Neuhaus PJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiac transplantation in man. Review of first three years' experience.
    Clark DA; Schroeder JS; Griepp RB; Stinson EB; Dong E; Shumway NE; Harrison DC
    Am J Med; 1973 May; 54(5):563-76. PubMed ID: 4573819
    [No Abstract]   [Full Text] [Related]  

  • 24. Heterotopic versus orthotopic heart transplantation.
    Barnard CN; Cooper DK
    Transplant Proc; 1984 Jun; 16(3):886-92. PubMed ID: 6375048
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical experience with antilymphocyte serum.
    Heyworth MF
    Immunol Rev; 1982; 65():79-97. PubMed ID: 6749648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart allograft rejection in rats triggered by H2 inhibitors.
    Olausson M; Wramner L; Blohmé I; Mjörnstedt L
    Transplant Proc; 1997 Nov; 29(7):3127-8. PubMed ID: 9365695
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunodulation of intestinal transplantation: antilymphocyte serum donor pretreatment vs. ex vivo graft irradiation.
    Nakao A; Nalesnik MA; Azhipa O; Ishikawa T; Abu-Elmagd K; Starzl TE; Murase N
    Transplant Proc; 2002 May; 34(3):986-7. PubMed ID: 12034273
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiac transplantation 1979.
    Bieber CP; Shumway NE
    Ann Thorac Surg; 1979 Sep; 28(3):205-7. PubMed ID: 158348
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination of antilymphocyte globulin and leflunomide leads to superior grafts.
    Woo J; Zhang W; Gao L; Shen J; Chong A; Buelow R
    Transplant Proc; 2001; 33(1-2):569. PubMed ID: 11266962
    [No Abstract]   [Full Text] [Related]  

  • 30. Patterns of thymocyte migration in unmodified and enhanced recipients of cardiac allografts.
    McKean WP; Baldwin WM; Tilney NL
    Surg Forum; 1979; 30():291-3. PubMed ID: 395685
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of steroid-resistant rejections with ATG and/or plasma filtration improves graft survival rates after cadaveric kidney transplantation.
    Fassbinder W; Bechstein PB; Stutte HJ; Scheuermann EH; Hanke P; Knöner M; Dathe G; Jonas D; Schoeppe W
    Neth J Med; 1985; 28(6):265-7. PubMed ID: 3892329
    [No Abstract]   [Full Text] [Related]  

  • 32. Transplantation of the lung.
    Blumenstock DA; Otte HP; Grosjean OB; Mulder MA
    Transplant Proc; 1969 Mar; 1(1):223-9. PubMed ID: 4944221
    [No Abstract]   [Full Text] [Related]  

  • 33. Transplantation.
    Wilson RE
    Surg Gynecol Obstet; 1976 Feb; 142(2):219-24. PubMed ID: 1108247
    [No Abstract]   [Full Text] [Related]  

  • 34. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy.
    Norman DJ
    Semin Nephrol; 1992 Jul; 12(4):315-24. PubMed ID: 1410859
    [No Abstract]   [Full Text] [Related]  

  • 35. Kidney transplantation from donors without a heartbeat.
    Luan FL
    N Engl J Med; 2002 Nov; 347(22):1799-801; author reply 1799-801. PubMed ID: 12462226
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiac transplantation: general considerations and results.
    Cooley DA; Bloodwell RD; Hallman GL; Leachman RD; Nora JJ; Milam JD
    Ann Surg; 1969 Jun; 169(6):892-905. PubMed ID: 4890293
    [No Abstract]   [Full Text] [Related]  

  • 37. Intrathymic injection of donor splenocytes plus systemic antilymphocyte serum or antilymphocyte serum alone prolongs cardiac allograft survival and inhibits graft arteriosclerosis in the Lewis-to-F344 chronic rejection model.
    Shin YT; Adams DH; Wyner LR; Akalin E; Sayegh MH; Karnovsky MJ
    Transplant Proc; 1995 Jun; 27(3):2112-4. PubMed ID: 7792902
    [No Abstract]   [Full Text] [Related]  

  • 38. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft.
    Nishimura Y; Tomikawa S; Ichikawa N; Kikuchi K; Ando Y; Meigata K; Nomura Y; Beck Y; Muto T
    Transplant Proc; 1998 Nov; 30(7):3850-1. PubMed ID: 9838684
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study.
    Chen GD; Lai XQ; Ko DS; Qiu J; Wang CX; Han M; Li J; Huang G; He XS; Chen LZ
    Nephrology (Carlton); 2015 Aug; 20(8):539-43. PubMed ID: 25808082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical significance of immunological findings for the survival time of kidney transplants with antilymphocyte globulin therapy].
    Bullinger W; Hammer C; Land W; Welter H
    Chir Forum Exp Klin Forsch; 1979; ():319-24. PubMed ID: 378592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.